Evidence map›Paper›PMID 39840467›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Therapeutic Black Phosphorus Nanosheets Elicit Neutrophil Response for Enhanced Tumor Suppression.

Jing Wang, Weiqiang Yu, Hui Shen, Yanxiang Sang, Hongjie Zhang, Benyan Zheng, Xue Peng, Yuan Hu, Xiaopeng Ma, Zhenye Yang and 1 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jing WangDepartment of General Surgery, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230036, P. R. China.
Weiqiang YuHIM-BGI Omics Center, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences (CAS), Hangzhou, P. R. China.
Hui ShenSchool of Life Science and Technology, China Pharmaceutical University.
Yanxiang SangState Key Laboratory of Fire Science, University of Science and Technology of China, Hefei, Anhui, 230036, P. R. China.
Hongjie ZhangState Key Laboratory of Fire Science, University of Science and Technology of China, Hefei, Anhui, 230036, P. R. China.
Benyan ZhengState Key Laboratory of Fire Science, University of Science and Technology of China, Hefei, Anhui, 230036, P. R. China.
Xue PengDepartment of General Surgery, The Chinese People's Armed Police Forces Anhui Provincial Corps Hospital, Hefei, Anhui Province, 234000, P. R. China.
Yuan HuState Key Laboratory of Fire Science, University of Science and Technology of China, Hefei, Anhui, 230036, P. R. China.
Xiaopeng MaDepartment of General Surgery, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230036, P. R. China.
Zhenye YangDepartment of Digestive Disease, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230036, P. R. China.
Fazhi YuDepartment of General Surgery, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230036, P. R. China.ORCID https://orcid.org/0000-0001-8586-0998

Funding

Anhui Province in 2022 Innovation and Entrepreneurship Support Plan Project 2022LCX031Fundamental Research Funds for the Central Universities YD9110002042National Key R&D Program of China 2022YFA1303100National Science Foundation of China 32370776;92357301;32170736Noncommunicable Chronic Diseases-National Science and Technology Major Project 2023ZD0507500Research Funds of Center for Advanced Interdisciplinary Science and Biomedicine of IHM of USTC QYPY20220017The Strategic Priority Research Program of the Chinese Academy of Sciences XDB0940101
6 · The paper itself

Abstract

Black phosphorus (BP) has demonstrated potential as a drug carrier and photothermal agent in cancer therapy; however, its intrinsic functions in cancer treatment remain underexplored. This study investigates the immunomodulatory effects of polyethylene glycol-functionalized BP (BP-PEG) nanosheets in breast cancer models. Using immunocompetent mouse models-including 4T1 orthotopic BALB/c mice and MMTV-PyMT transgenic mice, it is found that BP-PEG significantly inhibits tumor growth and metastasis without directly inducing cytotoxicity in tumor cells. Mass cytometry analysis reveals that BP-PEG reshapes the tumor immune microenvironment by recruiting neutrophils. Neutrophil depletion experiments further demonstrate that the antitumor effects of BP-PEG are dependent on neutrophils. Moreover, bulk and single-cell RNA sequencing indicate that BP-PEG is mainly taken up by macrophages, leading to the release of inflammatory factors such as IL1A and CXCL2, which enhance neutrophil recruitment and activation, thereby amplifying the antitumor immune response. Finally, co-culture assays confirm that BP-PEG indeed enhances the antitumor activity of neutrophils and natural killer (NK) cells. These findings position BP-PEG as an immunomodulatory agent capable of reprogramming the tumor microenvironment to promote innate immunity against breast cancer. By stimulating neutrophil-mediated antitumor activity, BP-PEG offers a unique therapeutic approach that can potentially enhance the efficacy of existing cancer immunotherapies.

Indexed as

Breast NeoplasmsNanostructuresNeutrophilsPhosphorusAnimalsCell Line, TumorFemaleHumansMiceMice, Inbred BALB CMice, TransgenicPolyethylene GlycolsTumor MicroenvironmentPhosphorusPolyethylene Glycolsblack phosphoruscancer therapyimmunomodulatoryneutrophil

Identifiers

PMID39840467
PMCPMC11984869

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.